MAR 2 6 2004 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

dia re Application of: WEI Ming-Hui, et al

Art Unit: 1652

Serial No.10/681,223

Examiner:

Filed: October 9, 2003

Atty. Docket: CL001305DIVII

For: Isolated Human Kinase Proteins, Nucleic Acid Molecules Encoding Human Kinase Proteins, And Uses

Thereof

Statement Regarding Duty Of Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Date March 26, 2004

Celera Genomics Corporation 45 West Gude Drive, C2-4#20

Rockville, MD 20850 Tel: 240-453-3067

Fax: 240-453-3084

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/P1O	
INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	

(use as many sheets as necessary)

Complete if Known 10/681,223 **Application Number** October 9, 2003 Filing Date WEI Ming-Hui, et al. First Named Inventor 1652 **Group Art Unit Examiner Name** Attorney Docket Number CL001305DIVII

Sheet

3			
8	,	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
;		Results of BLAST search of SEQ ID NO:2 against Derwent (FastAlert and GeneSeqP) and NCBI (pataa) protein patent databases on March 3, 2004. (14 pages)	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		Results of BLAST search of SEQ ID NO:2 against Genbank "nr" protein patent databases on March 3, 2004. (4 pages)	فنيهدس سناس
			ar Lida yanida
and sold the sec	al a Stavelle	and the second s	1
t seed a seed of design of			<u> </u>
		the second second control of the second of the second seco	
go tide was manage town t	epid Paped see		
	1000	angun dan mangun digun angun angun dan angun angun digung danggan dang	-
·	, pt (2004)	ing or all on the two constitutions and the contract of the co	
	;		4
en embru yan	* ***		
		,	

_		 communication description of a second second second	5.4-						
•			2 STE # JF	O 1 500 TV	Walter Carrier Ca	177 1	77"	17 .17 W .4VIT W.	
	Examiner			1	Date:				
	7.50,111,01,1			1	Date				-1
١.	Signature			1.	Considered				
	O GUIGUALO I	 			CONSIGNICA				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MREP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.